Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath (R)) on a compassionate basis. A report on efficacy and safety of CAM 511 trial.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Rai, KR; Keating, MJ; Coutre, S; Rizzieri, DA; Grp, CS

Published Date

  • November 16, 2002

Published In

Volume / Issue

  • 100 / 11

Start / End Page

  • 802A - 802A

International Standard Serial Number (ISSN)

  • 0006-4971